Background/Objectives: Surgery is the primary treatment for early-stage lung cancer. Patients with medically inoperable lung carcinomas and patients who refuse to undergo surgery are treated with definite radiotherapy. Stereotactic ablative radiotherapy (SABR) is a compelling non-invasive therapeutic modality for this group of patients that confers promising results. Methods: We report an interim analysis of an ongoing trial. Eighty-one patients with medically inoperable early-stage (T1,2N0) lung cancer underwent SABR in our institution. SABR was delivered via the CyberKnife M6 robotic radiosurgery system. The endpoints of the analysis were treatment efficacy and tolerance. Results: There were no acute or late toxicities from the skin or the connective tissue of the thorax. A grade 2/3 lung injury of non-clinical significance was noted in 6% of patients, which was directly related to a higher biologically effective dose (BEDα/β = 3) and larger irradiation lung volumes in both univariate and multivariate analyses. A local control (LC) was achieved in 100% of the patients at the first follow-up, and the projected 24-month local progression-free survival (LPFS) rate was 95%. The projected 24-month disease-specific overall survival (OS) was 94%. Conclusions: High LC and OS rates can be achieved with SABR for early-stage lung cancer, with minimal toxicity. This study continues to recruit patients.
背景/目的：手术是早期肺癌的主要治疗手段。对于医学上无法手术的肺癌患者以及拒绝接受手术的患者，通常采用根治性放疗进行治疗。立体定向消融放疗（SABR）是这类患者一种极具吸引力的非侵入性治疗方式，并展现出良好的疗效。方法：本文报告了一项正在进行中的试验的中期分析结果。81例医学上无法手术的早期（T1、2N0期）肺癌患者在我院接受了SABR治疗。SABR通过射波刀M6机器人放射外科系统实施。分析的主要终点是治疗效果和耐受性。结果：未观察到皮肤或胸部结缔组织的急性或晚期毒性反应。6%的患者出现了无临床意义的2/3级肺损伤，单变量和多变量分析均显示，这与较高的生物有效剂量（BEDα/β = 3）和较大的肺部照射体积直接相关。首次随访时，所有患者均实现了局部控制（LC），预计24个月局部无进展生存率（LPFS）为95%。预计24个月疾病特异性总生存率（OS）为94%。结论：SABR治疗早期肺癌可实现较高的局部控制率和总生存率，且毒性反应极小。本研究仍在继续招募患者。
肿瘤(癌症)患者之家